BioNTech SE · NASDAQ:BNTX
BioNTech — Q2 2025 Earnings Presentation
34 slides from BioNTech's earnings presentation, Aug 4, 2025
Slide 1: 2nd Quarter 2025 Financial Results & Corporate Update
2nd Quarter 2025 Financial Results & Corporate Update August 4th, 2025
Slide 2: This Slide Presentation Includes Forward-Looking Statements
This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profit/
Slide 3: Agenda
1 2nd Quarter 2025 Update Ugur Sahin, Co-founder & Chief Executive Officer 2 Oncology Pipeline Update Özlem Türeci, Co-founder & Chief Medical Officer 3 Financial Update Ramón Zapata, Chief Financial Officer 4 Strategic Outlook Ryan Richardson, Chief Strategy Officer
Slide 4: 2nd Quarter 2025 Update
1 2nd Quarter 2025 Update Ugur Sahin, Co-founder & Chief Executive Officer
Slide 5: Building a Global Immunotherapy Powerhouse
Building a Global Immunotherapy Powerhouse Translating Science into Survival
Slide 6: Our Priorities are Our Novel mRNA Cancer Immunotherapies and Our Next-Generation IO-Backbone
Our Priorities are Our Novel mRNA Cancer Immunotherapies and Our Next-Generation IO-Backbone Novel mRNA cancer immunotherapies Our next-generation IO-backbone FixVac & iNeST1 PD-L1/VEGF-A antibody BNT3272 Next-generation of personalized cancer therapy targeting Potential to become the next-generatio
Slide 7: Q2 2025+ Progress Towards Our Strategic Goals
Q2 2025+ Progress Towards Our Strategic Goals Execution in oncology • Progressing broad pan-tumor development plan spearheaded by Phase 3 trials in lung and breast cancer BNT3271 • Announced global strategic partnership with BMS to co-develop and co-commercialize BNT3271 • Achieved FPD in trials eva
Slide 8: BioNTech and BMS Enter Landmark Strategic Collaboration to Advance BNT327
BioNTech and BMS Enter Landmark Strategic Collaboration to Advance BNT3271 Anti-VEGF-A Maximizing potential of next-generation immunomodulator BNT3271 with global co-development and co-commercialization partnership • Bispecific antibody targeting PD-L1 and VEGF-A • Over 1,200 patients treated in cli
Slide 9: Harnessing Complementary Expertise to Maximize BNT327 Potential
Harnessing Complementary Expertise to Maximize BNT3271 Potential Patient-centric scientific excellence ➢ Unique pipeline enabling ➢ Global clinical development multiple potential BNT3271 expertise in novel and combinations for solid tumors United in oncology combination therapies; (e.g., ADCs, mRNA)
Slide 10: Oncology Pipeline Update
2 Oncology Pipeline Update Özlem Türeci, Co-founder & Chief Medical Officer
Slide 11: Advancing Towards Commercial Stage in Oncology
Advancing Towards Commercial Stage in Oncology mRNA Cancer BNT3271 Immunotherapies BNT323/DB-13032 Aim to accelerate and expand BNT3271 mRNA cancer immunotherapy data Advance BNT323/DB-13032 towards development with strategic BMS expected in late 2025 or early 2026 BLA submission in EC and BC collab
Slide 12: BNT327 Synergistic Targeting of PD-L1 and VEGF
BNT3271 Synergistic Targeting of PD-L1 and VEGF NSCLC IHC2 Bispecific MOA Tumor microenvironment VEGF-A VEGF-A dimer (TME) Local neutralization of in the TME PD-L1 ligand angiogenic and on tumor cells immunosuppressive Anti-VEGF-A (Fab) Anti-PD-L1 (VHH) VEGF-A effects BNT327 Anti-PD-L1 (VHH) Anti-VE
Slide 13: Accelerating and Broadening BNT327 Global Clinical Development
Accelerating and Broadening BNT3271 Global Clinical Development Exploring the potential of BNT3271 in three waves of focused development 1 Establish 2 Combine 3 Broaden • Two Phase 2 dose optimization trials • Three Phase 1/2 and one Phase 2 ongoing in TNBC and SCLC with data combination trials with
Slide 14: Establish: BNT327 Combined With Chemotherapy in 1L ES-SCLC Phase 2
Establish: BNT3271 Combined With Chemotherapy Indicated Encouraging Efficacy in 1L ES-SCLC in Phase 2 Study Unmet medical need remains high for patients with ES-SCLC Global Phase 3 study ongoing Patients with ES-SCLC2 have a 5-year survival rate of 3% (ROSETTA Lung-01) Phase 2 Study (NCT05844150):
Slide 15: Establish: BNT327 Monotherapy Efficacy in 1L NSCLC
Establish: BNT3271 Monotherapy Efficacy in 1L NSCLC Phase 1b/2a (NCT05918445): cohort 1, 1L NSCLC (EGFR & ALK WT) Global Phase 2/3 study ongoing Wu, C. et al. presented at ASCO 2024. Poster #8533. (ROSETTA Lung-02) Indication Benchmark regimen ORR mPFS mOS Benchmark study Waterfall/spider plots and
Slide 16: Establish: BNT327 Combined With Chemotherapy in 1L TNBC
Establish: BNT3271 Combined With Chemotherapy Indicated Encouraging Efficacy in 1L TNBC Irrespective of PD-L1 Status in Phase 1/2 Study Unmet medical need remains high for patients with TNBC Global Phase 3 planned for 2025 Patients with Stage IV TNBC2 have a 5-year survival rate of 10% (ROSETTA Brea
Slide 17: Accelerating and Broadening BNT327 Global Clinical Development
Accelerating and Broadening BNT3271 Global Clinical Development Exploring the potential of BNT3271 in three waves of focused development 1 Establish 2 Combine 3 Broaden Ongoing Ongoing • Phase 2 in TNBC • Phase 1/2 with BNT325/DB-13052 Diverse portfolio of clinical oncology • Phase 2 in SCLC (TROP2)
Slide 18: Combine: BNT327 with Novel ADCs in High Unmet Need Indications
Combine: BNT3271 with Novel ADCs in High Unmet Need Indications Preliminary data combining BNT3271 with BNT325/DB-13052 showed a manageable safety profile with few overlapping toxicities and signs of clinical activity Phase 1/2 (NCT05438329): BNT3271 combined with TROP2 ADC BNT325/DB-13052 in 2L–4L
Slide 19: Accelerating and Broadening BNT327 Global Clinical Development
Accelerating and Broadening BNT3271 Global Clinical Development Exploring the potential of BNT3271 in three waves of focused development 1 Establish 2 Combine 3 Broaden Ongoing Ongoing Diverse portfolio of clinical oncology assets in-house • Phase 2 in TNBC • Phase 1/2 with BNT325/DB- • Combine with
Slide 20: Leveraging Our Leadership in mRNA to Fully Exploit Cancer Immunotherapy Target Space
Leveraging Our Leadership in mRNA to Fully Exploit Cancer Immunotherapy Target Space with Two Approaches Artificial Individual intelligence-driven Individualized patient samples neoantigen immuno- Individualized (blood and tissue) prediction therapy 10.3% Neoantigens therapy Mutant Neoantigen TNBC,
Slide 21: Clinical Trial Execution Across iNeST and FixVac Portfolios
Clinical Trial Execution Across iNeST and FixVac Portfolios Individualized immunotherapy: iNeST FixVac Autogene cevumeran (BNT122/RO7198457)1 BNT1112 BNT113 BNT116 Adjuvant 1L R/R R/R 1L Multiple settings MIUC CRC PDAC Melanoma Solid tumors Melanoma HPV16+ HNSCC NSCLC Phase 2 Phase 2 Phase 2 Phase 2
Slide 22: Financial Update
3 Financial Update Ramón Zapata, Chief Financial Officer
Slide 23: Q2 and H1 Financial Results
Q2 and H1 Financial Results (in millions €, except per share data)1 Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Revenues 261 129 444 316 Cost of Sales (76) (60) (160) (119) Research and Development Expenses (509) (585) (1,035) (1,092) Sales and Marketing Expenses (19.7)
Slide 24: BMS Partnership Aims to Strengthen Cash Position and P&L for Multiple Years
BMS Partnership Aims to Strengthen Cash Position and P&L for Multiple Years1 Payment Anticipated Cash Effect Anticipated Revenue Effect Revenue recognition over the Upfront Cash Payment $1.5 bn Q3 2025 development phase Non-Contingent Anniversary Revenue recognition over the $2.0 bn 2026 - 2028 Cash
Slide 25: 2025 Financial Year Guidance Reaffirmed
2025 Financial Year Guidance Reaffirmed1 FY 2025 Guidance Planned FY 2025 Revenues €1,700 – €2,200 m revenues R&D expenses €2,600 – €2,800 m Planned FY 2025 SG&A expenses €650 – €750 m expenses and capex Capital expenditure for operating activities €250 – €350 m Relatively stable pricing and market
Slide 26: Strategic Outlook
4 Strategic Outlook Ryan Richardson, Chief Strategy Officer
Slide 27: Strategic Priority Areas in 2025
Strategic Priority Areas in 2025 mRNA cancer immunotherapy Oncology commercial readiness » Expect first randomized data » Advance BNT323/DB-13031 in the adjuvant setting (CRC) towards BLA submission in late 2025 or early 2026 » Continue to build targeted » Continue to execute 6 ongoing AI-enabled co
Slide 28: Save the date
Save the date Innovation Series: AI Day October 1, 2025 London, UK Innovation Series R&D Day November 11, 2025 New York, NY U.S.
Slide 29: Thank you
—_ Thank you BIONT=Cr
Slide 30: Appendix
__. Appendix BIONT=Cr
Slide 31: Selected Pipeline Milestones in 2025 and Beyond
Selected Pipeline Milestones in 2025 and Beyond Demonstrate Continued Progress Across Priority Programs Program Indication 2025+ Milestone 1L/2L SCLC Global Phase 2 dose optimization data Next-generation BNT3271 immunomodulator 1L/2L TNBC Global Phase 2 dose optimization data Autogene cevumeran ctDN
Slide 32: BioNTech's Oncology Pipeline – Phase 2 and Phase 3 Clinical Trials
BioNTech’s Oncology Pipeline – Phase 2 and Phase 3 Clinical Trials Phase 2 Phase 3 BNT113 Autogene cevumeran (BNT122/RO7198457)1 BNT327 (PD-L1 x VEGF-A) 1L rel./met. HPV16+ PD-L-1+ HNC, Adj. ctDNA+ stage II or III CRC 2L NSCLC, + CTx + pembrolizumab BNT327 (PD-L1 x VEGF-A) BNT327 (PD-L1 x VEGF-A) Au
Slide 33: BioNTech's Oncology Pipeline – Phase 1 and Phase 1/2 Clinical Trials
BioNTech’s Oncology Pipeline – Phase 1 and Phase 1/2 Clinical Trials Phase 1 Phase 1/2 Autogene cevumeran (BNT122/RO7198457)1 BNT312/GEN10422 (CD40x4-1BB) BNT327 (PD-L1 x VEGF-A) Multiple solid tumors Multiple solid tumors 1L TNBC7 BNT116 BNT316/ONC-392 (gotistobart)5 (CTLA-4) BNT327 (PD-L1 x VEGF-A
Slide 34: Abbreviation Directory
Abbreviation Directory nL nth line FixVac Fixed Antigen Vaccine PDAC Pancreatic ductal adenocarcinoma AACR American Association for Cancer Research FPD First patient dosed PD-(L)1 Programmed cell death protein (ligand) 1 ADC Antibody-drug conjugate HCC Hepatocellular carcinoma PFS Progression-free s